We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Proteomic Prediction and Renin Angiotensin Aldosterone System Inhibition Prevention Of Early Diabetic nephRopathy In TYpe 2 Diabetic Patients With Normoalbuminuria (PRIORITY)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02040441
Recruitment Status : Active, not recruiting
First Posted : January 20, 2014
Last Update Posted : February 21, 2018
Mosaiques Diagnostics GmbH
University Medical Center Groningen
University of Glasgow
Istituto Di Ricerche Farmacologiche Mario Negri
Univerzita Karlova v Praze
Geniko Nosokomeio Athinas Ippokrateio
Institut Klinické a Experimentální Mediciny Praze
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
Klinikum St. Georg Leipzig
Cyril and Methodius University in Skopje
Hannover Clinical Trial Center
European Commission
Diabetes Vascular Research Foundation Hoogeveen
Universitair Ziekenhuis Gent
Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden
Stichting VUMC
Diabetologen Hessen
Information provided by (Responsible Party):
Peter Rossing, Steno Diabetes Center